Skip to main content

Sulfasalazine Enteric-Coated and Immediate-Release Tablets Shortage

Last Updated: September 7, 2023
Status: Current

Products Affected - Description
    • Sulfasalazine tablet, Teva, 500 mg, bottle, 100 count, NDC 00093-3234-01
    • Sulfasalazine tablet, Teva, 500 mg, bottle, 500 count, NDC 00093-3234-05
    • Sulfasalazine tablet, Teva, 500 mg, bottle, 1000 count, NDC 00093-3234-10
Reason for the Shortage
    • Viatris did not provide a reason for the shortage.
    • Teva did not provide a reason for the shortage.
    • Pfizer has Azulfidine and Azulfidine Entabs available.
Available Products
    • Azulfidine Entabs coated tablet, Pfizer, 500 mg, bottle, 100 count, NDC 00013-0102-50
    • Azulfidine Entabs coated tablet, Pfizer, 500 mg, bottle, 300 count, NDC 00013-0102-60
    • Sulfasalazine coated tablet, Greenstone (Viatris), 500 mg, bottle, 100 count, NDC 59762-0104-05
    • Sulfasalazine coated tablet, Greenstone (Viatris), 500 mg, bottle, 300 count, NDC 59762-0104-06
    • Azulfidine tablet, Pfizer, 500 mg, bottle, 100 count, NDC 00013-0101-10
    • Azulfidine tablet, Pfizer, 500 mg, bottle, 300 count, NDC 00013-0101-30
    • Sulfasalazine tablet, Greenstone (Viatris), 500 mg, bottle, 100 count, NDC 59762-5000-05
    • Sulfasalazine tablet, Greenstone (Viatris), 500 mg, bottle, 300 count, NDC 59762-5000-06

Estimated Resupply Dates

    • Teva has sulfasalazine immediate-release 500 mg tablets in 100 count, 500 count, and 1,000 count bottles on back order and the company estimates a release date of September 2023.

Updated

Updated September 7, 2023 by Michelle Wheeler, PharmD, Drug Information Specialist. Created January 8, 2020 by Rachael Freeman, PharmD, BCPS. © 2023, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer